Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy

Rheumatology (United Kingdom)

Volumn 53, Issue 3, 2014, Pages 397-405

  Venalis, Paulius ^a   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adaptive immunity; Anti Jo 1; Antisynthetase autoantibodies; Cytotoxic T cells; Dermatomyositis; Immunotherapies; Interstitial lung disease; Polymyositis

Indexed keywords

ADAPTIVE IMMUNITY; ANTI-JO-1; ANTISYNTHETASE AUTOANTIBODIES; CYTOTOXIC T CELLS; DERMATOMYOSITIS; IMMUNOTHERAPIES; INTERSTITIAL LUNG DISEASE; POLYMYOSITIS;

AUTOANTIBODIES; DERMATOMYOSITIS; HUMANS; IMMUNOTHERAPY; MUSCLE WEAKNESS; MUSCLE, SKELETAL; POLYMYOSITIS; T-LYMPHOCYTES;

EID: 84894335051     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket279     Document Type: Review

References (76)

1. Hengstman GJ, Brouwer R, Egberts WT et al. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies. J Neurol 2002;249:69-75.
2. Marguerie C, Bunn CC, Beynon HL et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 1990;77:1019-38.
3. *03) with polymyositis and dermatomyositis. Arthritis Rheum 2004;50:1013-5.
4. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984;16:209-15.
5. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
6. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther 2011;13:209.
7. Rutjes SA, Vree Egberts WT, Jongen P et al. Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997;109:32-40.
8. Selva-O'Callaghan A, Labrador-Horrillo M, Solans-Laque R et al. Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. Arthritis Rheum 2006;55:791-8.
9. Stone KB, Oddis CV, Fertig N et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007;56:3125-31.
10. Hervier B, Devilliers H, Stanciu R et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012;12:210-7.
11. Miller FW, Love LA, Barbieri SA et al. Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups. Clin Exp Immunol 1990;81:373-9.
12. Mathews MB, Reichlin M, Hughes GR et al. Anti-threonyltRNA synthetase, a second myositis-related autoantibody. J Exp Med 1984;160:420-34.
13. Bunn CC, Bernstein RM, Mathews MB. Autoantibodies against alanyl-tRNA synthetase and tRNAAla coexist and are associated with myositis. J Exp Med 1986;163:1281-91.
14. Targoff IN. Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis. J Immunol 1990;144:1737-43.
15. Hirakata M, Suwa A, Takada T et al. Clinical and immunogenetic features of patients with autoantibodies to asparaginyl-transfer RNA synthetase. Arthritis Rheum 2007;56:1295-303.
16. Hirakata M, Suwa A, Nagai S et al. Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. J Immunol 1999;162:2315-20.
17. Betteridge Z, Gunawardena H, North J et al. Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology 2007;46:1005-8.
18. Hashish L, Trieu EP, Sadanandan P et al. Identification of autoantibodies to tyrosyl-tRNA synthetase in dermatomyositis with features consistent with anti-synthetase syndrome (abstract). Arthritis Rheum 2005;52:S312.
19. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis-characterization of the Jo-1 antibody system. Arthritis Rheum 1980;23:881-8.
20. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry 2000;68:472-8.
21. Levine SM, Raben N, Xie D et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum 2007;56:2729-39.
22. Howard OM, Dong HF, Yang D et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med 2002;196:781-91.
23. Wakasugi K, Schimmel P. Highly differentiated motifs responsible for two cytokine activities of a split human tRNA synthetase. J Biol Chem 1999;274:23155-9.
24. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science 1999;284:147-51.
25. Soejima M, Kang EH, Gu X et al. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum 2011;63:479-87.
26. Levine SM, Rosen A, Casciola-Rosen LA. Anti-aminoacyl tRNA synthetase immune responses: insights into the pathogenesis of the idiopathic inflammatory myopathies. Curr Opin Rheumatol 2003;15:708-13.
27. Eloranta ML, Barbasso Helmers S, Ulfgren AK et al. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24.
28. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208.
29. Wang DX, Lu X, Zu N et al. Clinical significance of peripheral blood lymphocyte subsets in patients with polymyositis and dermatomyositis. Clin Rheumatol 2012;31:1691-7.
30. Greenberg SA, Bradshaw EM, Pinkus JL et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology 2005;65:1782-7.
31. Ishii W, Matsuda M, Shimojima Y et al. Flow cytometric analysis of lymphocyte subpopulations and TH1/TH2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008;47:1593-9.
32. Bradshaw EM, Orihuela A, McArdel SL et al. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007;178:547-56.
33. Krystufkova O, Vallerskog T, Helmers SB et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis 2009;68:836-43.
34. Peng QL, Xie Y, Zhang RF et al. [The levels and clinical significance of serum B cell activating factor in Chinese patients with polymyositis or dermatomyositis]. Zhonghua Nei Ke Za Zhi 2012;51:210-3.
35. Couderc M, Gottenberg JE, Mariette X et al. Efficacy and safety of rituximab in the treatment of refractory inflammatory myopathies in adults: results from the AIR registry. Rheumatology 2011;50:2283-9.
36. Limaye V, Hissaria P, Liew CL et al. Efficacy of rituximab in refractory antisynthetase syndrome. Intern Med J 2012;42:e4-7.
37. Oddis CV, Reed AM, Aggarwal R et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:314-24.
38. Lindberg C, Oldfors A, Tarkowski A. Restricted use of T cell receptor V genes in endomysial infiltrates of patients with inflammatory myopathies. Eur J Immunol 1994;24:2659-63.
39. Englund P, Wahlstrom J, Fathi M et al. Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum 2007;56:372-83.
40. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cellmediated cytotoxicity in myopathies. Hum Pathol 1989;20:224-31.
41. Pedrol E, Grau JM, Casademont J et al. Idiopathic inflammatory myopathies. Immunohistochemical analysis of the major histocompatibility complex antigen expression, inflammatory infiltrate phenotype and activation cell markers. Clin Neuropathol 1995;14:179-84.
42. Zong M, Loell I, Lindroos E et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor alpha expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2012;71:1055-63.
43. Fasth AE, Dastmalchi M, Rahbar A et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol 2009;183:4792-9.
44. Fasth AE, Bjorkstrom NK, Anthoni M et al. Activating NK-cell receptors co-stimulate CD4(+)CD28(-) T cells in patients with rheumatoid arthritis. Eur J Immunol 2010;40:378-87.
45. Loell IM, Pandya J, Raghavan S et al. Persisting CD28(null) T cells, but not regulatory T cells, in muscle tissue of myositis patients after immunosuppressive therapy (abstract). Arthritis Rheum 2011;63:S86.
46. Venalis P, Pandya J, Stache V et al. CD28null T cells from myositis patients are cytotoxic to autologous muscle cells in vitro. Arthritis Rheum 2011;63:S323-4.
47. Kondo M, Murakawa Y, Harashima N et al. Roles of proinflammatory cytokines and the Fas/Fas ligand interaction in the pathogenesis of inflammatory myopathies. Immunology 2009;128(Suppl. 1):e589-99.
48. Chevrel G, Page G, Granet C et al. Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003;137:125-33.
49. Tournadre A, Porcherot M, Cherin P et al. Th1 and Th17 balance in inflammatory myopathies: interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009;46:297-301.
50. Waschbisch A, Schwab N, Ruck T et al. Wiendl H. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol 2010;225:137-42.
51. Swainson LA, Mold JE, Bajpai UD et al. Expression of the autoimmune susceptibility gene FcRL3 on human regulatory T cells is associated with dysfunction and high levels of programmed cell death-1. J Immunol 2010;184:3639-47.
52. Dalakas MC, Rakocevic G, Schmidt J et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusionbody myositis. Brain 2009;132(Pt 6):1536-44.
53. Nguyen CQ, Yin H, Lee BH et al. IL17: potential therapeutic target in Sjogren's syndrome using adenovirus-mediated gene transfer. Lab Invest 2011;91:54-62.
54. Ginzler E, Furie R, Wallace D et al. Novel combined response endpoint shows that belimumab (fully human monoclonal antibody to B-LYMPHOCYTE stimulator [blys]) improves or stabilizes SLE disease activity in a phase 2 trial. Ann Rheum Dis 2007;66(Suppl. 2):56.
55. Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, doseranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78.
56. St Pierre BA, Kasper CE, Lindsey AM. Fatigue mechanisms in patients with cancer: effects of tumor necrosis factor and exercise on skeletal muscle. Oncol Nurs Forum 1992;19:419-25.
57. Kokkola R, Li J, Sundberg E et al. Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity. Arthritis Rheum 2003;48:2052-8.
58. Diaz-Gonzalez F, Alten RH, Bensen WG et al. Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:628-32.
59. Greenberg SA, Pinkus JL, Pinkus GS et al. Interferonalpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005;57:664-78.
60. Walsh RJ, Kong SW, Yao Y et al. Type I interferoninducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92.
61. Eloranta ML, Lovgren T, Finke D et al. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum 2009;60:2418-27.
62. Higgs BW, Zhu W, Morehouse C et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-alpha monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis 2013. Advance Access published 23 February 2013, doi: 10.1136/annrheumdis-2012-202794.
63. Furlan A, Botsios C, Ruffatti A et al. Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine 2008;75:366-7.
64. Zong M, Dorph C, Dastmalchi M et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow up. Ann Rheum 2013. Advance Access published 26 April 2013, doi:10.1136/annrheumdis-2012-202857.
65. Dastmalchi M, Grundtman C, Alexanderson H et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:1670-7.
66. Amato AA, Tawil R, Kissel J et al. A randomized, pilot trial of etanercept in dermatomyositis the muscle study group. Ann Neurol 2011;70:427-36.
67. Narazaki M, Hagihara K, Shima Y et al. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology 2011;50:1344-6.
68. Okiyama N, Sugihara T, Iwakura Y et al. Therapeutic effects of interleukin-6 blockade in a murine model of polymyositis that does not require interleukin-17A. Arthritis Rheum 2009;60:2505-12.
69. Tucci M, Quatraro C, Dammacco F et al. Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol 2006;146:21-31.
70. Hong K, Oh K, Lee S et al. Recombinant Fc-IL-18BPc isoform inhibits IL-18-induced cytokine production. Hybridoma 2012;31:99-104.
71. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol 2012;8:195-202.
72. Ulfgren AK, Grundtman C, Borg K et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum 2004;50:1586-94.
73. Grundtman C, Bruton J, Yamada T et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J 2010;24:570-8.
74. Korotkova M, Helmers SB, Loell I et al. Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2008;67:1596-602.
75. Loell I, Alemo Munters L, Pandya J et al. Activated LTB4 pathway in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis 2013;72:293-9.
76. Del Prete A, Shao WH, Mitola S et al. Regulation of dendritic cell migration and adaptive immune response by LTB4 receptors: a role for LTB4 in up-regulation of CCR7 expression and function. Blood 2007;109:626-31.